Advancing oncology data and AI infrastructure across the drug lifecycle
BOCA RATON, Fla.–(BUSINESS WIRE)–Massive Bio, Inc., an agentic AI and real-world data company advancing oncology drug development and access, today announced its inclusion in TIME’s World’s Top HealthTech Companies 2026 in the AI & Data Analytics category. Produced in collaboration with Statista, the list recognizes 500 companies worldwide based on financial performance, reputation and online engagement.
The recognition comes as Massive Bio expands its role as oncology data and AI infrastructure. The company brings together patient-consented clinical and molecular information, specialized AI agents and a global network of patients, physicians and life-sciences organizations. This foundation supports a broader business spanning clinical development, commercialization and real-world evidence, connecting what happens in a patient’s cancer journey with decisions across the drug lifecycle.
“Massive Bio is building the data and AI infrastructure for the oncology drug lifecycle,” said Selin Kurnaz, PhD, Co-Founder and Chief Executive Officer of Massive Bio. “Our work with patients and life-sciences partners has created a foundation that extends across research, evidence generation and treatment access. TIME’s recognition is an important milestone as we scale that platform. The opportunity is to help our partners understand where innovation is needed, develop therapies more effectively and reach the patients who need them.”
At the center of this strategy is Reticulum Nexus™ (RNex), Massive Bio’s multi-agent AI platform. The company is developing RNex as an oncology agent foundry: an architecture that assembles specialized AI capabilities around an evolving patient record. Its purpose is to connect changes in diagnosis, biomarkers, treatment and access barriers to the next appropriate action, while preserving the clinical context needed throughout the patient’s journey.
For pharmaceutical and biotechnology companies, the platform’s expanding applications include identifying relevant patient populations, assessing study feasibility, understanding biomarker and treatment patterns, and informing access and commercialization strategies. NexusPulse™ supports oncology signal intelligence, while Patient Connect™ and TrialRelay™ connect patient engagement and physician workflows. Together, these capabilities underpin the company’s strategy to turn longitudinal data into useful evidence and coordinated action.
“We are developing RNex so that specialized agents can work from a shared understanding of the patient,” said Çağatay Çulcuoğlu, Co-Founder, Chief Technology Officer and Chief Operating Officer of Massive Bio. “Our architecture combines oncology knowledge graphs, clinical data and AI reasoning to coordinate defined tasks across programs. We are industrializing the oncology next-action layer: turning a relevant signal into a coordinated, traceable action. Reusable agents and shared clinical context are central to making that infrastructure scale.”
Massive Bio has onboarded more than 200,000 cancer patients and operates across 17 countries. Its scientific foundation includes a peer-reviewed prospective evaluation of its AI-assisted trial-matching workflow in 3,804 patients, published in ESMO Real World Data and Digital Oncology. The study processed more than 157,000 pages of clinical documentation and reported more than 17,000 oncologist-confirmed matches.
Building on this foundation, Massive Bio’s development roadmap includes longitudinal patient digital twins and oncology world models for research into disease trajectories, treatment pathways and access. These efforts aim to connect patient-level intelligence with predictive modeling and simulation, creating additional applications for drug development and real-world evidence generation.
“Cancer changes over time, and the intelligence supporting a patient must change with it,” said Arturo Loaiza-Bonilla, MD, MSEd, FACP, Co-Founder and Chief Medical AI Officer of Massive Bio. “A new biomarker, a treatment transition or an access barrier should trigger an informed next step. Our ambition is to make every patient’s journey a discovery engine. With patient consent and clinicians guiding decisions, multi-agent AI can connect care with research so that what we learn from one patient helps shape better options for the next.”
View the TIME World’s Top HealthTech Companies 2026 list.
About Massive Bio
Massive Bio is an agentic AI and real-world data (RWD) company advancing oncology drug development, commercialization, and access to precision medicine. Powered by RNex (Reticulum Nexus™), its platform combines patient-consented multimodal data and clinical intelligence to identify patients, support trial enrollment, and generate real-world evidence. Massive Bio serves pharmaceutical and biotechnology companies, CROs, providers, and researchers across clinical development, commercial strategy, market access, care navigation, and provider engagement. Founded by Selin Kurnaz, Arturo Loaiza-Bonilla, M.D., and Çağatay Çulcuoğlu, Massive Bio operates in 17 countries and is an OpenAI Select Partner, recipient of the DiMe Seal, founding member of CancerX, and participant in the White House Cancer Moonshot initiative.
For more information, visit massivebio.com.
Contacts
Media Contact
Mert Turkkan
Marketing Director
Massive Bio
[email protected]
